BriaPro Advances Novel Anti-Cancer Antibody Development

BriaCell Therapeutics ( (TSE:BCT) ) has shared an announcement.

BriaCell’s subsidiary, BriaPro, is advancing the development of novel antibodies targeting the B7-H3 antigen, a promising target in cancer treatment due to its high expression on tumor and immune cells. These antibodies are expected to be integrated into BriaPro’s proprietary Bria-TILsRx™ platform, which aims to enhance T cell activity against tumors, potentially offering significant therapeutic benefits across multiple cancer types. The company has filed for US patents and plans to seek international patent protection, positioning itself as a key player in the immuno-oncology space.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

BriaCell Therapeutics’ overall score reflects the company’s challenging financial position, with no revenue generation and consistent operational losses, posing significant financial risks. Technical analysis suggests a bearish trend, while valuation highlights concerns about profitability. However, recent corporate events are promising, with advancements in immunotherapy and successful financing efforts providing some upside potential.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. Its subsidiary, BriaPro Therapeutics Corp., is a pre-clinical stage company dedicated to creating binding agents and proteins aimed at enhancing the body’s natural cancer-fighting capabilities.

YTD Price Performance: -51.93%

Average Trading Volume: 10,808

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$21.66M

See more insights into BCT stock on TipRanks’ Stock Analysis page.